BCL6-IN-4 is a potent B-cell lymphoma 6 (BCL6) inhibitor with an IC50 of 97 nM. BCL6-IN-4 has anti-tumor activities[1].
BCL6-IN-4 (compound 25b) inhibits OCI-Ly1 and OCI-Ly3 cell lines growth with GI50 values of 2.8 μM and 4.2 μM, respectively[1].
[1]. Benjamin R Bellenie, et al. Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem. 2020 Apr 23;63(8):4047-4068.
















